Xinghan De Biotechnology

Xinghan De Biotechnology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to developing innovative T-cell receptor engineered T-cell (TCR-T) therapies for solid tumors. The company utilizes a proprietary high-throughput TCR discovery and optimization platform to identify potent TCRs targeting viral antigens and tumor-specific neoantigens. Its lead candidate, XHD-001, is an autologous TCR-T therapy targeting the HPV16 E7 oncoprotein, currently undergoing Phase 1 clinical evaluation for HPV-positive malignancies including cervical and head and neck cancers. Beyond viral targets, Xinghan De is advancing a robust pipeline of TCR-T programs focused on common driver mutations such as KRAS, aiming to provide effective treatments for gastrointestinal and lung cancers. The company is supported by prominent venture capital firms and maintains collaborations with leading Chinese clinical institutions to accelerate its translational research.